SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 15
Certification and Notice of Termination of Registration under
Section 12(g) of the Securities Exchange Act of 1934 or
Suspension of Duty to File Reports Under Sections 13
and 15(d) of the Securities Exchange Act of 1934
Commission File Number 1-10827
PHARMACEUTICAL RESOURCES, INC.
(Exact name of registrant as specified in its charter)
One Ram Ridge Road, Spring Valley, New York 10977, (914) 425-7100
(Address, including zip code, and telephone number, including
area code, of registrant's principal executive offices)
Series A Convertible Preferred Stock, $.0001 per share
(Title of each class of securities covered by this Form)
Common Stock, $.01 par value
Common Stock Purchase Rights
(Titles of all other classes of securities for which a duty to
file reports under Section 13(a) or 15(d) remains)
Please place an X in the box(es) to designate the
appropriate rule provision(s) relied upon to terminate or suspend
the duty to file reports:
Rule 12g-4(a)(1)(i) [ x ] Rule 12h-3(b)(1)(ii) [ ]
Rule 12g-4(a)(1)(ii) [ ] Rule 12h-3(b)(2)(i) [ ]
Rule 12g-4(a)(2)(i) [ ] Rule 12h-3(b)(2)(ii) [ ]
Rule 12g-4(a)(2)(ii) [ ] Rule 15d-6 [ ]
Rule 12h-3(b)(1)(i) [ ]
Approximate number of holders of record as of the
certification or notice date: 0
Pursuant to the requirements of the Securities Exchange
Act of 1934 Pharmaceutical Resources, Inc. has caused this
certification/notice to be signed on its behalf by the
undersigned duly authorized person.
Date: January 3, 1996 By: Robert I. Edinger
----------------------------
Robert I. Edinger, Executive
Vice President, Chief
Financial Officer and Secretary
